{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 17,
  "pageCount": 58,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "data_table",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The chart displays 4 categories of FDA designations with stacked segments representing product types.",
  "elementsJson": [
    "headline_text",
    "bar_chart_stacked",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/17",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-17",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Around 30% of Chinese biopharmas' products with FDA designation are self-claimed first/best-in-class",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbb-b976b9a0724f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.52,
        "w": 0.55,
        "x": 0.038,
        "y": 0.32
      },
      "kind": "chart",
      "text": "Stacked bar chart showing product counts by designation type",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a422df9-cc38-42de-a735-eb6bcbbefb66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.67,
        "y": 0.4
      },
      "kind": "list",
      "text": "FDA has developed four programs to facilitate and expedite the development of new drugs. Around 30% of Chinese biopharmas' products with FDA designation are self-claimed first/best-in-class.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e82f048-fab6-4fc0-91e0-0ab83abb6806",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Number of products: 21",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbb-bd97297becc5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.038,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "Note: *FDA designs four special designations to facilitate and expedite the review of drugs to get important new drugs to the patient earlier; **Based on notes in Pharmaprojects for each trial, as FDA has not disclosed such data. Source: U.S. FDA, Pharmaprojects, L.E.K. analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b3dee8f-2719-4602-ae3a-20a807f9a2b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.038,
        "y": 0.06
      },
      "kind": "title",
      "text": "Some innovative assets also managed to obtain FDA special designation through filling unmet needs on serious conditions or significant improvement on effectiveness",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "672a6fc7-d6fc-4e5f-a53e-07c29104f6e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.55,
        "x": 0.038,
        "y": 0.22
      },
      "kind": "title",
      "text": "Number of Chinese biopharmas' products with FDA special designation* (not exclusive**) (2017-21)",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96cfb22c-5fac-4033-bbd5-02a9b4bbf566",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Number of products",
      "numberRaw": "21",
      "numberKind": "plain",
      "actionTitle": "Some innovative assets also managed to obtain FDA special designation through filling unmet needs on serious conditions or significant improvement on effectiveness",
      "calloutText": "Around 30% of Chinese biopharmas' products with FDA designation are self-claimed first/best-in-class",
      "numberScale": null,
      "numberValue": 21,
      "metricFamily": "volume_count",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 12,
      "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f",
      "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.",
      "position": 0,
      "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}